ZEALAND PHARMA A/S (22Z.DE) Stock Fundamental Analysis
Europe - FRA:22Z - DK0060257814 - Common Stock
68.28 EUR
+0.06 (+0.09%)
Taking everything into account, 22Z scores 6 out of 10 in our fundamental rating. 22Z was compared to 73 industry peers in the Biotechnology industry. 22Z is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. 22Z is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 22Z was profitable.
22Z had a positive operating cash flow in the past year.
22Z had negative earnings in each of the past 5 years.
In the past 5 years 22Z always reported negative operating cash flow.
1.2 Ratios
22Z has a better Return On Assets (38.89%) than 98.63% of its industry peers.
22Z has a Return On Equity of 42.80%. This is amongst the best in the industry. 22Z outperforms 95.89% of its industry peers.
22Z's Return On Invested Capital of 32.36% is amongst the best of the industry. 22Z outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 38.89% | ||
| ROE | 42.8% | ||
| ROIC | 32.36% |
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
22Z has a better Profit Margin (73.34%) than 97.26% of its industry peers.
22Z has a better Operating Margin (81.00%) than 98.63% of its industry peers.
The Gross Margin of 22Z (100.06%) is better than 95.89% of its industry peers.
22Z's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 81% | ||
| PM (TTM) | 73.34% | ||
| GM | 100.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
2. Health
2.1 Basic Checks
22Z has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
22Z has more shares outstanding than it did 1 year ago.
22Z has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 22Z has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 12.09 indicates that 22Z is not in any danger for bankruptcy at the moment.
22Z's Altman-Z score of 12.09 is amongst the best of the industry. 22Z outperforms 91.78% of its industry peers.
The Debt to FCF ratio of 22Z is 0.05, which is an excellent value as it means it would take 22Z, only 0.05 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 22Z (0.05) is better than 98.63% of its industry peers.
22Z has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
22Z has a better Debt to Equity ratio (0.02) than 72.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.05 | ||
| Altman-Z | 12.09 |
ROIC/WACC4.64
WACC6.98%
2.3 Liquidity
22Z has a Current Ratio of 15.09. This indicates that 22Z is financially healthy and has no problem in meeting its short term obligations.
22Z has a Current ratio of 15.09. This is amongst the best in the industry. 22Z outperforms 94.52% of its industry peers.
A Quick Ratio of 15.08 indicates that 22Z has no problem at all paying its short term obligations.
22Z has a better Quick ratio (15.08) than 94.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.09 | ||
| Quick Ratio | 15.08 |
3. Growth
3.1 Past
22Z shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 921.54%, which is quite impressive.
Looking at the last year, 22Z shows a very strong growth in Revenue. The Revenue has grown by 2375.69%.
22Z shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.69% yearly.
EPS 1Y (TTM)921.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2404.28%
Revenue 1Y (TTM)2375.69%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%26527.65%
3.2 Future
Based on estimates for the next years, 22Z will show a decrease in Earnings Per Share. The EPS will decrease by -2.54% on average per year.
Based on estimates for the next years, 22Z will show a very strong growth in Revenue. The Revenue will grow by 123.26% on average per year.
EPS Next Y638.53%
EPS Next 2Y82.04%
EPS Next 3Y9.07%
EPS Next 5Y-2.54%
Revenue Next Year11614.8%
Revenue Next 2Y668.41%
Revenue Next 3Y251.45%
Revenue Next 5Y123.26%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.37, which indicates a rather cheap valuation of 22Z.
Based on the Price/Earnings ratio, 22Z is valued cheaper than 94.52% of the companies in the same industry.
When comparing the Price/Earnings ratio of 22Z to the average of the S&P500 Index (27.90), we can say 22Z is valued rather cheaply.
The Price/Forward Earnings ratio is 23.85, which indicates a rather expensive current valuation of 22Z.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 22Z indicates a rather cheap valuation: 22Z is cheaper than 82.19% of the companies listed in the same industry.
22Z's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.37 | ||
| Fwd PE | 23.85 |
4.2 Price Multiples
22Z's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 22Z is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.13 | ||
| EV/EBITDA | -0.27 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y82.04%
EPS Next 3Y9.07%
5. Dividend
5.1 Amount
22Z does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:22Z (10/6/2025, 7:00:00 PM)
68.28
+0.06 (+0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners48.71%
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner ChangeN/A
Market Cap3.15B
Analysts85
Price Target109.28 (60.05%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-314.33%
Min EPS beat(2)-623.11%
Max EPS beat(2)-5.54%
EPS beat(4)1
Avg EPS beat(4)-152.35%
Min EPS beat(4)-623.11%
Max EPS beat(4)23.23%
EPS beat(8)3
Avg EPS beat(8)-58.82%
EPS beat(12)5
Avg EPS beat(12)-38.11%
EPS beat(16)7
Avg EPS beat(16)-28.16%
Revenue beat(2)0
Avg Revenue beat(2)-39.07%
Min Revenue beat(2)-74.61%
Max Revenue beat(2)-3.53%
Revenue beat(4)0
Avg Revenue beat(4)-58.45%
Min Revenue beat(4)-92.1%
Max Revenue beat(4)-3.53%
Revenue beat(8)4
Avg Revenue beat(8)65%
Revenue beat(12)6
Avg Revenue beat(12)54.69%
Revenue beat(16)6
Avg Revenue beat(16)27.38%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.37 | ||
| Fwd PE | 23.85 | ||
| P/S | 2.58 | ||
| P/FCF | 3.13 | ||
| P/OCF | 3.12 | ||
| P/B | 1.51 | ||
| P/tB | 1.51 | ||
| EV/EBITDA | -0.27 |
EPS(TTM)12.72
EY18.63%
EPS(NY)2.86
Fwd EY4.19%
FCF(TTM)21.85
FCFY32%
OCF(TTM)21.9
OCFY32.08%
SpS26.45
BVpS45.33
TBVpS45.29
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 38.89% | ||
| ROE | 42.8% | ||
| ROCE | 45.97% | ||
| ROIC | 32.36% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 81% | ||
| PM (TTM) | 73.34% | ||
| GM | 100.06% | ||
| FCFM | 82.59% |
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
F-Score8
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.05 | ||
| Debt/EBITDA | 0.05 | ||
| Cap/Depr | 77.22% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 405.42 | ||
| Cash Conversion | 101.88% | ||
| Profit Quality | 112.62% | ||
| Current Ratio | 15.09 | ||
| Quick Ratio | 15.08 | ||
| Altman-Z | 12.09 |
F-Score8
WACC6.98%
ROIC/WACC4.64
Cap/Depr(3y)51.82%
Cap/Depr(5y)53.82%
Cap/Sales(3y)13.05%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)921.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2404.28%
EPS Next Y638.53%
EPS Next 2Y82.04%
EPS Next 3Y9.07%
EPS Next 5Y-2.54%
Revenue 1Y (TTM)2375.69%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%26527.65%
Revenue Next Year11614.8%
Revenue Next 2Y668.41%
Revenue Next 3Y251.45%
Revenue Next 5Y123.26%
EBIT growth 1Y1123.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year744.74%
EBIT Next 3Y22.1%
EBIT Next 5Y15.77%
FCF growth 1Y1062.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1078.6%
OCF growth 3YN/A
OCF growth 5YN/A